Skip to main content
Clinical Trials/ACTRN12616001727437
ACTRN12616001727437
Recruiting
N/A

Effect of sequential use of noninvasive ventilation (NIV) and high flow nasal therapy (HFNT) after early extubation on re-intubation rate in chest trauma patients recovering from hypoxemic acute respiratory failure: a single-center feasibility study

niversity of Palermo. Pocliclinico P. Giaccone0 sites30 target enrollmentDecember 16, 2016

Overview

Phase
N/A
Intervention
Not specified
Conditions
chest trauma
Sponsor
niversity of Palermo. Pocliclinico P. Giaccone
Enrollment
30
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
December 16, 2016
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Palermo. Pocliclinico P. Giaccone

Eligibility Criteria

Inclusion Criteria

  • All of the following:
  • 1\) age equal or higher than 18 years;
  • 2\) Invasive Mechanical Ventilation (iMV) for at least 24h;
  • 3\) pressure support ventilation (PSV) with a total applied pressure, i.e. positive end\-expiratory pressure (PEEP) inspiratory support, \< 20 cmH2O and a PEEP level between 8 and 10 cmH2O;
  • 4\) PaO2/FiO2 between 200 and 300 mmHg
  • 5\) PaCO2 \< 45mmHg and pH \> 7\.35;
  • 6\) respiratory rate (RR) \< 30/min;
  • 7\) core temperature \< 38\.5 degree Celtius; (8\)
  • 8\) Glasgow coma scale (GCS) equal or higher than 11;
  • 9\) Richmond Agitation Sedation Score \< 3;

Exclusion Criteria

  • One of the following:
  • 1\) hemodynamic instability i.e. systolic arterial pressure \< 90 mmHg despite fluid repletion;
  • 2\) use of vasoactive agents, i.e. vasopressin, epinephrine and norepinephrine at any dosage, and dopamine or dobutamine \> 5mcg/kg/min;
  • 3\) life\-threatening arrhythmias or electrocardiographic signs of ischemia;
  • 4\) sepsis or septic shock;
  • 5\) ARF secondary to neurological disorders, status asthmaticus, COPD, cardiogenic pulmonary oedema;
  • 6\) presence of tracheotomy;
  • 7\) uncontrolled vomiting;
  • 8\) uncontrolled agitation RASS \>3 5;
  • 9\) two or more organ failures;

Outcomes

Primary Outcomes

Not specified

Similar Trials